The high-tech Nuclear Medicine Molybdenum-99 (Mo-99) manufacturing facility provides ANSTO with the manufacturing capacity to meet more than a quarter of the world’s demand for Mo-99. This critical life-saving radioisotope is required by healthcare providers both in Australia and overseas for use in nuclear medicine procedures. The active pharmaceutical ingredient is used in more than 45 million procedures each year for the diagnosis of cancers and heart disease and it’s estimated that half of all Australians will benefit from its use in their lifetime. The new facility has almost tripled ANSTO’s manufacturing capability of Mo-99. The number one priority for the new facility was delivering solutions to meet the highest standards of safety and security.